Revlimid lenalidomide regulatory update

Celgene disclosed in its 2Q12 earnings that it submitted an MAA to EMA to expand the label of multiple myeloma (MM) drug Revlimid lenalidomide to include treatment of myelodysplastic syndromes (MDS) in patients with 5q chromosomal deletion. Celgene markets the thalidomide analog in the U.S. and EU in combination with dexamethasone to treat MM in patients who have received at least 1 prior therapy and in the U.S. to treat patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS. ...